Initiate clinical trial for BEAM-302 ex-U.S
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Jan 2024
- Due
- 30 Jun 2024
- Delivered
- June 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate clinical trial for BEAM-302 ex-U.S. in first half of 2024”
What we found
Evidence strength D What the grades mean
Beam initiated the BEAM-302 clinical trial ex-U.S. in June 2024, within the first half 2024 deadline, with first patient dosing announced in that month.
-
D Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
“The company expects to initiate the Phase 1/2 trial of BEAM-302 in the UK in the first half of 2024.”
-
D Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
“In June, Beam announced that the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe AATD that is currently being evaluated in a Phase 1/2 clinical trial.”
Checked 5 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 8 Jan 2024
Deadline 30 Jun 2024 (“first half of 2024”)
-
Version 2 · stated 27 Feb 2024
Deadline 30 Jun 2024 (“first half of 2024”) · wording expected
“plans to initiate a Phase 1 clinical trial for BEAM-302 in the first half of 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- BEAM-302 clinical trial
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: assuming CTA acceptance
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-BEAM-003261 · Corrections policy